User profiles for "author:Anna Goodman"
 | Anna GoodmanLondon School of Hygiene and Tropical Medicine Verified email at lshtm.ac.uk Cited by 13446 |
Does more cycling mean more diversity in cycling?
In low-cycling countries, cycling is not evenly distributed across genders and age groups. In
the UK, men are twice as likely as women to cycle to work and cycling tends to be dominated …
the UK, men are twice as likely as women to cycle to work and cycling tends to be dominated …
Cycling provision separated from motor traffic: a systematic review exploring whether stated preferences vary by gender and age
In this paper, we represent a systematic review of stated preference studies examining the
extent to which cycle infrastructure preferences vary by gender and by age. A search of …
extent to which cycle infrastructure preferences vary by gender and by age. A search of …
[HTML][HTML] Nonantibiotic prevention and management of recurrent urinary tract infection
N Sihra, A Goodman, R Zakri, A Sahai… - Nature Reviews …, 2018 - nature.com
Urinary tract infections (UTIs) are highly prevalent, lead to considerable patient morbidity,
incur large financial costs to health-care systems and are one of the most common reasons …
incur large financial costs to health-care systems and are one of the most common reasons …
[HTML][HTML] Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South …
Background A safe and efficacious vaccine against severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control …
coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control …
[HTML][HTML] Clinical features and management of human monkeypox: a retrospective observational study in the UK
H Adler, S Gould, P Hine, LB Snell, W Wong… - The Lancet Infectious …, 2022 - thelancet.com
Background Cases of human monkeypox are rarely seen outside of west and central Africa.
There are few data regarding viral kinetics or the duration of viral shedding and no licensed …
There are few data regarding viral kinetics or the duration of viral shedding and no licensed …
[HTML][HTML] Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a …
Summary Background The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for
emergency use by the UK regulatory authority, Medicines and Healthcare products …
emergency use by the UK regulatory authority, Medicines and Healthcare products …
[HTML][HTML] Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study
Summary Background The Pfizer-BioNTech (BNT162b2) and the Oxford-AstraZeneca
(ChAdOx1 nCoV-19) COVID-19 vaccines have shown excellent safety and efficacy in phase …
(ChAdOx1 nCoV-19) COVID-19 vaccines have shown excellent safety and efficacy in phase …
[HTML][HTML] Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV …
Background Few data exist on the comparative safety and immunogenicity of different
COVID-19 vaccines given as a third (booster) dose. To generate data to optimise selection …
COVID-19 vaccines given as a third (booster) dose. To generate data to optimise selection …
[HTML][HTML] Safety and efficacy of NVX-CoV2373 Covid-19 vaccine
PT Heath, EP Galiza, DN Baxter, M Boffito… - … England Journal of …, 2021 - Mass Medical Soc
Background Early clinical data from studies of the NVX-CoV2373 vaccine (Novavax), a
recombinant nanoparticle vaccine against severe acute respiratory syndrome coronavirus 2 …
recombinant nanoparticle vaccine against severe acute respiratory syndrome coronavirus 2 …
[HTML][HTML] Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B. 1.1. 7): an exploratory analysis of a randomised …
Background A new variant of SARS-CoV-2, B. 1.1. 7, emerged as the dominant cause of
COVID-19 disease in the UK from November, 2020. We report a post-hoc analysis of the …
COVID-19 disease in the UK from November, 2020. We report a post-hoc analysis of the …